X4 Pharma’s Success After Cutbacks Will Comfort Hard-Hit Biotechs
Cost-Cutting And Focus On Lead Asset Pays Off
Executive Summary
X4 Pharma has shown that cutting back and focusing on a lead asset can work but mavorixafor’s first-in-class status and efficacy profile is not common.
You may also be interested in...
Keeping Track: Rybrevant Goes RTOR, Two-Part Review For Dasiglucagon, And CRL For Ultomiris
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Finance Watch: Sage Warns Of Job Cuts, Joins Peers Making Cash Last After Setbacks
Public Company Edition: Sage will reveal cost reductions later in the third quarter after the US FDA approved zuranolone for the smaller of two depression indications. Also, Karyopharm revealed a 20% workforce reduction, Harmony accessed up to $185m in debt and Astellas invested $50m in Poseida.
Two Cardiovascular Trial Hits Get Merck & Co.’s Blood Pumping
Merck has taken two important steps towards its goal of achieving eight new cardiovascular drug approvals by 2030, presenting promising data for two potential blockbusters at the ACC meeting.